Long-term results of a randomised phase III trial of weekly versus three-weekly paclitaxel/platinum induction therapy followed by standard or extended three-weekly paclitaxel/plati... von van der Burg, M.E.L, Onstenk, W, Boere, I.A, Look, M, Ottevanger, P.B, de Gooyer, D, Kerkhofs, L.G.M, Valster, F.A.A, Ruit, J.B, van Reisen, A.G.P.M, Goey, S.H, van der Torren, A.M.E, ten Bokkel Huinink, D, Kok, T.C, Verweij, J, van Doorn, H.C

Volltext

Long-term results of weekly paclitaxel carboplatin induction therapy: An effective and well-tolerated treatment in patients with platinum-resistant ovarian cancer von van der Burg, M.E.L, Vergote, I, Onstenk, W, Boere, I.A, Leunen, K, van Montfort, C.A.G.M, van Doorn, H.C

Volltext

Chemosensitivity and outcome of BRCA1- and BRCA2-associated ovarian cancer patients after first-line chemotherapy compared with sporadic ovarian cancer patients von Vencken, P.M.L.H., Kriege, M., Hoogwerf, D., Beugelink, S., van der Burg, M.E.L., Hooning, M.J., Berns, E.M., Jager, A., Collée, M., Burger, C.W., Seynaeve, C.

Volltext

3BA Randomized MRC OV05/EORTC 55955 trial in recurrent ovarian cancer: early treatment based on increased serum CA125 alone versus delayed treatment based on conventional clinical... von van der Burg, M.E.L, Rustin, G.J

Volltext

Randomized phase III trial of bleomycin, vindesine, mitomycin-C, and cisplatin (BEMP) versus cisplatin (P) in disseminated squamous-cell carcinoma of the uterine cervix: An EORTC G... von Vermorken, J. B., Zanetta, G., De Oliveira, C. F., van der Burg, M. E. L., Lacave, A. J., Teodorovic, I., Boes, G. Hoctin, Colombo, N.

Volltext

Dose-dense therapy is of benefit in primary treatment of ovarian cancer: contra von van der Burg, M E L, Boere, I A, Berns, P M J J

Volltext

8006 Improved outcome after first line chemotherapy in BRCA1- and BRCA2-associated ovarian cancer compared with sporadic ovarian cancer patients von Seynaeve, C, Hoogwerf, D, Kriege, M, Beugelink, S, Jager, A, Collee, J, Berns, E.M, Burg van der, M.E.L, Burger, C.W, Vencken, P

Volltext

The role of CA 125 in the early diagnosis of progressive disease in ovarian cancer von van der Burg, M.E.L., Lammes, F.B., Verweij, J.

Volltext

Ovarian cancer: The prognostic value of the serum half-life of CA125 during induction chemotherapy von van der Burg, M.E.L., Lammes, F.B., van Putten, W.L.J., Stoter, G.

Volltext

Weekly high-dose cisplatin in malignant pleural mesothelioma von Planting, A. S. T., Schellens, J. H. M., Goey, S. H., van der Burg, M. E. L., de Boer-Dennert, M., Stoter, G., Verweij, J.

Volltext

Alterations in the p53 pathway and prognosis in advanced ovarian cancer: A multi-factorial analysis of the EORTC Gynaecological Cancer group (study 55865) von Green, J.A., Berns, E.M.J.J., Coens, C., van Luijk, I., Thompson-Hehir, J., van Diest, P., Verheijen, R.H.M., van de Vijver, M., van Dam, P., Kenter, G.G., Tjalma, W., Ewing, P.C., Teodorovic, I., Vergote, I., van der Burg, M.E.L.

Volltext

Phase I Study of High-Dose Epirubicin in Platinum-Pretreated Patients with Ovarian Carcinoma von Vermorken, J.B., ten Bokkel Huinink, W.W., Kobierska, A., van der Burg, M.E.L., Forni, M., Piccart, M.J., van der Putten, E.

Volltext

Preoperative Predictors for Residual Tumor after Surgery in Patients with Ovarian Carcinoma von de Jong, D., Eijkemans, M.J., Lie Fong, S., Gerestein, C.G., Kooi, G.S., Baalbergen, A., van der Burg, M.E.L., Burger, C.W., Ansink, A.C.

Volltext

Phase II study of bleomycin, vindesine, mitomycin C and cisplatin (BEMP) in recurrent or disseminated squamous cell carcinoma of the uterine cervix von van Luijk, I.F., Coens, C., van der Burg, M.E.L., Kobierska, A., Namer, M., Lhomme, C., Zola, P., Zanetta, G., Vermorken, J.B.

Volltext

Dose-dense cisplatin/paclitaxel: a well-tolerated and highly effective chemotherapeutic regimen in patients with advanced ovarian cancer von de Jongh, F.E, de Wit, R, Verweij, J, Sparreboom, A, van den Bent, M.J, Stoter, G, van der Burg, M.E.L

Volltext

Consolidation therapy for advanced ovarian cancer von van der Burg, M.E.L.

Volltext

Phase II study of neo-adjuvant chemotherapy with paclitaxel and cisplatin given every 2 weeks for patients with a resectable squamous cell carcinoma of the esophagus von Polee, M. B., Tilanus, H. W., Eskens, F. A. L. M., Hoekstra, R., Van der Burg, M. E. L., Siersema, P. D., Stoter, G., Van der Gaast, A.

Volltext

Retreatment with dose-dense weekly cisplatin after previous cisplatin chemotherapy is not complicated by significant neuro-toxicity von van den Bent, M.J, van Putten, W.L.J, Hilkens, P.H.E, de Wit, R, van der Burg, M.E.L

Volltext

Weekly Carboplatin Combination Therapy is Also More Effective in Platinum-Resistant Ovarian Cancer von van der Burg, M.E.L., Vergote, I., Burger, C.W., van Doorn, H.C., Leunen, K., Amant, F., van der Gaast, A.

Volltext

271 Dose-Dense Weekly Paclitaxel (T) Carboplatin (C) is A Highly Active and Well-Tolerated Treatment in Platinum and Paclitaxel Pretreated Progressive Ovarian Cancer von van der Burg, M.E.L., Vergote, I., Burger, C.W., van der Gaast, A., Leunen, K., Graveland, W.J.

Volltext